coadministered cagrilintide and semaglutide in adults with overweight or obesity New the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Coadministered Cagrilintide and Semaglutide, in

Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks

Offer: modified-release metformin, and an SGLT-2 inhibitor If metformin is contraindicated or not tolerated, offer monotherapy with an SGLT-2 inhibitor

Our approach combines evidence-based microdosing strategies with cutting-edge aesthetic treatments specifically designed for GLP-1 patients

Every treatment plan should be individualized and medically supervised. Rosemary Daly, D.O., DABPM Florida Surgery & Weight Loss Center offers physician-guided peptide therapy consultations for eligible patients interested in healthy aging, recovery support, energy optimization, sleep quality, and overall wellness

We can answer all your questions so you're confident you take all the proper steps